
    
      This is a prospective non-randomized longitudinal study. One hundred subjects will
      participate in 6 monthly and 3 bi-monthly serial assessments of plasma-based BNP, implantable
      device measured intrathoracic impedance, and clinical evaluation of heart failure status.
      Each patient will be enrolled in the study for a period of 12 months.
    
  